↓ Skip to main content

Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma

Overview of attention for article published in Strahlentherapie und Onkologie, September 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
22 Mendeley
Title
Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma
Published in
Strahlentherapie und Onkologie, September 2015
DOI 10.1007/s00066-015-0892-5
Pubmed ID
Authors

Margret Rave-Fränk, Narges Tehrany, Julia Kitz, Martin Leu, Hanne Elisabeth Weber, Peter Burfeind, Henning Schliephake, Martin Canis, Tim Beissbarth, Holger Michael Reichardt, Hendrik Andreas Wolff

Abstract

The chemokine CXCL12 and its receptor CXCR4 can affect tumor growth, recurrence, and metastasis. We tested the hypothesis that the CXCL12 and CXCR4 expression influences the prognosis of patients with inoperable head and neck cancer treated with definite radiotherapy or chemoradiotherapy. Formalin-fixed paraffin-embedded pretreatment tumor tissue from 233 patients with known HPV/p16(INK4A) status was analyzed. CXCL12 and CXCR4 expressions were correlated with pretreatment parameters and survival data by univariate and multivariate Cox regression. CXCL12 was expressed in 43.3 % and CXCR4 in 66.1 % of the samples and both were correlated with HPV/p16(INK4A) positivity. A high CXCL12 expression was associated with increased overall survival (p = 0.036), while a high CXCR4 expression was associated with decreased metastasis-free survival (p = 0.034). A high CXCR4 expression could be regarded as a negative prognostic factor in head and neck cancer because it may foster metastatic spread. This may recommend CXCR4 as therapeutic target for combating head and neck cancer metastasis.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Unknown 22 100%
Readers by discipline Count As %
Unknown 22 100%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2016.
All research outputs
#10,837,407
of 12,225,678 outputs
Outputs from Strahlentherapie und Onkologie
#240
of 319 outputs
Outputs of similar age
#200,656
of 243,792 outputs
Outputs of similar age from Strahlentherapie und Onkologie
#8
of 15 outputs
Altmetric has tracked 12,225,678 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 319 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,792 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.